Researchers are exploring various immunotherapy options for treating autoimmune encephalitis, with some studies indicating improved response rates or reduced relapse rates with certain treatments. However, high relapse rates and rare cases of treatment-induced autoimmune encephalitis have also been reported, highlighting the complexity of the condition. Different therapies, including IVIG, pembrolizumab, rituximab, and telitacicept, are being investigated for their potential effectiveness in managing autoimmune encephalitis.